Access the full text.
Sign up today, get DeepDyve free for 14 days.
Maneesh Sud, Lu Han, M. Koh, H. Abdel-Qadir, P. Austin, M. Farkouh, L. Godoy, P. Lawler, J. Udell, H. Wijeysundera, D. Ko (2020)
Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention.Journal of the American College of Cardiology, 76 12
H. Quan, V. Sundararajan, P. Halfon, A. fong, B. Burnand, J. Luthi, L. Saunders, C. Beck, T. Feasby, W. Ghali (2005)
Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 43
Ž. Reiner, A. Catapano, Guy Backer, I. Graham, M. Taskinen, O. Wiklund, S. Agewall, E. Alegrı́a, M. Chapman, P. Durrington, S. Erdine, J. Halcox, Richard Hobbs, J. Kjekshus, P. Filardi, G. Riccardi, Robert Storey, D. Wood (2013)
ESC/EAS Guidelines for the Management of DyslipidaemiasRevista Portuguesa De Pneumologia, 32
B. Gencer, F. Mach, S. Murphy, G. Ferrari, K. Huber, B. Lewis, J. Ferreira, C. Kurtz, Hong Wang, Narimon Honarpour, A. Keech, P. Sever, T. Pedersen, M. Sabatine, R. Giugliano (2020)
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.JAMA cardiology
M. Sabatine, R. Giugliano, A. Keech, Narimon Honarpour, S. Wiviott, S. Murphy, J. Kuder, Huei Wang, Thomas Liu, S. Wasserman, P. Sever, T. Pedersen (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England Journal of Medicine, 376
R. Giugliano, T. Pedersen, Jeong-Gun Park, G. Ferrari, Z. Gaciong, R. Češka, K. Tóth, I. Gouni-Berthold, J. López-Miranda, F. Schiele, F. Mach, B. Ott, Estella Kanevsky, A. Pineda, R. Somaratne, S. Wasserman, A. Keech, P. Sever, M. Sabatine (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialThe Lancet, 390
EC McKinley, Vanessa Bittner, Tm Brown, L. Chen, LD Colantonio, J. Exter, KK Orroth, SR Reading, RS Rosenson, P. Muntner (2021)
Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.Journal of clinical lipidology
(2022)
OUP accepted manuscriptEuropean Heart Journal - Quality of Care and Clinical Outcomes
Gregory Schwartz, G. Steg, M. Szarek, Deepak Bhatt, Vera Bittner, Rafael Diaz, Jay Edelberg, Shaun Goodman, C. Hanotin, Robert Harrington, Wouter Jukema, G. Lecorps, K. Mahaffey, A. Moryusef, R. Pordy, K. Quintero, Matthew Roe, W. Sasiela, J. Tamby, P. Tricoci, Harvey White, Andreas Zeiher (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeThe New England Journal of Medicine, 379
C. Baigent, L. Blackwell, J. Emberson, L. Holland, C. Reith, N. Bhala, R. Peto, E. Barnes, A. Keech, J. Simes, R. Collins (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsLancet, 376
Guanmin Chen, M. Farris, T. Cowling, L. Pinto, R. Rogoza, Erin Mackinnon, Salimah Champsi, Todd Anderson (2021)
Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real‐world evidence studyClinical Cardiology, 44
(Gupta M, Mancini GBJ, Wani RJ, Ahooja V, Bergeron J, Manjoo P, et al. Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. CJC Open.)
Gupta M, Mancini GBJ, Wani RJ, Ahooja V, Bergeron J, Manjoo P, et al. Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. CJC Open.Gupta M, Mancini GBJ, Wani RJ, Ahooja V, Bergeron J, Manjoo P, et al. Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. CJC Open., Gupta M, Mancini GBJ, Wani RJ, Ahooja V, Bergeron J, Manjoo P, et al. Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study. CJC Open.
J. Grégoire, Salimah Champsi, M. Jobin, Laura Martínez, M. Urbich, R. Rogoza (2022)
Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in CanadaAdvances in Therapy, 39
D. Lloyd‐Jones, P. Morris, C. Ballantyne, K. Birtcher, Ashleigh Covington, Sondra Depalma, M. Minissian, C. Orringer, Sidney Smith, A. Waring, J. Wilkins (2022)
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.Journal of the American College of Cardiology
S. Grundy, N. Stone, Alison Bailey, Craig Beam, K. Birtcher, R. Blumenthal, L. Braun, S. Ferranti, Joseph Faiella-Tommasino, D. Forman, Ronald Goldberg, P. Heidenreich, M. Hlatky, Daniel Jones, D. Lloyd‐Jones, Nuria Lopez-Pajares, C. Ndumele, C. Orringer, C. Peralta, J. Saseen, Sidney Smith, L. Sperling, S. Virani, J. Yeboah (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Journal of the American College of Cardiology, 73 24
S. Murphy, C. Cannon, M. Blazing, R. Giugliano, Jennifer White, Y. Lokhnygina, C. Reist, K. Im, E. Bohula, D. Isaza, J. López-Sendón, M. Dellborg, U. Kher, A. Tershakovec, E. Braunwald (2016)
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.Journal of the American College of Cardiology, 67 4
P. Halfon, Y. Eggli, G. Melle, J. Chevalier, J. Wasserfallen, B. Burnand (2002)
Measuring potentially avoidable hospital readmissions.Journal of clinical epidemiology, 55 6
C. Cannon, M. Blazing, R. Giugliano, A. McCagg, Jennifer White, P. Théroux, H. Darius, B. Lewis, T. Ophuis, J. Jukema, G. Ferrari, W. Rużyłło, Paul Lucca, K. Im, E. Bohula, C. Reist, S. Wiviott, A. Tershakovec, T. Musliner, E. Braunwald, R. Califf (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.The New England journal of medicine, 372 25
R. Deyo, D. Cherkin, D. Cherkin, M. Ciol (1992)
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.Journal of clinical epidemiology, 45 6
J. Tu, Anam Khan, Kelvin Ng, A. Chu (2017)
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact.The Canadian journal of cardiology, 33 3
C. Derington, Lisandro Colantonio, Jennifer Herrick, James Cook, Jordan King, R. Rosenson, B. Poudel, K. Monda, A. Navar, K. Mues, V. Stevens, R. Nelson, Megan Vanneman, P. Muntner, A. Bress (2021)
Factors Associated With PCSK9 Inhibitor Initiation Among US VeteransJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 10
(2019)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)Eur Heart J, 41
M. Gupta, G. Mancini, R. Wani, V. Ahooja, J. Bergeron, P. Manjoo, A. Pandey, M. Reiner, Johnny Beltrán, T. Oliveira, Erin Mackinnon (2022)
Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI StudyCJC Open, 4
M. Charlson, P. Pompei, Kathy Ales, C. MacKenzie (1987)
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.Journal of chronic diseases, 40 5
(2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelinesCirculation, 139
W. Friedewald, R. Levy, D. Fredrickson (1972)
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clinical chemistry, 18 6
(Grégoire J, Champsi S, Jobin M, Martinez L, Urbich M, Rogoza RM. Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. Advances in Therapy. 2022.)
Grégoire J, Champsi S, Jobin M, Martinez L, Urbich M, Rogoza RM. Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. Advances in Therapy. 2022.Grégoire J, Champsi S, Jobin M, Martinez L, Urbich M, Rogoza RM. Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. Advances in Therapy. 2022., Grégoire J, Champsi S, Jobin M, Martinez L, Urbich M, Rogoza RM. Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada. Advances in Therapy. 2022.
G. Pearson, G. Thanassoulis, T. Anderson, A. Barry, P. Couture, N. Dayan, G. Francis, J. Genest, J. Grégoire, S. Grover, M. Gupta, R. Hegele, D. Lau, Lawrence Leiter, A. Leung, E. Lonn, G. Mancini, P. Manjoo, R. McPherson, D. Ngui, M. Piché, P. Poirier, J. Sievenpiper, J. Stone, R. Ward, W. Wray (2021)
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.The Canadian journal of cardiology
B. Sarak, A. Savu, P. Kaul, F. McAlister, R. Welsh, A. Yan, S. Goodman (2021)
Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary SyndromeCirculation: Cardiovascular Quality and Outcomes, 14
F. Mach, C. Baigent, A. Catapano, K. Koskinas, M. Casula, L. Badimón, M. Chapman, G. Backer, V. Delgado, B. Ference, I. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T. Pedersen, G. Riccardi, D. Richter, M. Sabatine, M. Taskinen, L. Tokgozoglu, O. Wiklund, S. Windecker, V. Aboyans, J. Collet, V. Dean, D. Fitzsimons, C. Gale, D. Grobbee, S. Halvorsen, G. Hindricks, B. Iung, P. Jüni, H. Katus, C. Leclercq, M. Lettino, B. Lewis, B. Merkely, Christian Mueller, Steffen Petersen, A. Petronio, M. Roffi, E. Shlyakhto, I. Simpson, M. Sousa‐Uva, R. Touyz, D. Nibouche, P. Zelveian, P. Siostrzonek, R. Najafov, P. Borne, B. Pojskić, A. Postadzhiyan, Lambros Kypris, J. Špinar, M. Larsen, H. Eldin, M. Viigimaa, T. Strandberg, J. Ferrières, R. Agladze, U. Laufs, L. Rallidis, L. Bajnok, T. Gudjonsson, V. Maher, Y. Henkin, M. Gulizia, A. Mussagaliyeva, Gani Bajraktari, A. Kerimkulova, G. Latkovskis, O. Hamoui, R. Šlapikas, Laurent Visser, P. Dingli, V. Ivanov, A. Bošković, M. Nazzi, F. Visseren, I. Mitevska, K. Retterstøl, P. Jankowski, R. Fontes-Carvalho, D. Gaita, M. Ezhov, M. Foscoli, V. Giga, D. Pella, Z. Fras, L. Isla, E. Hagström, R. Lehmann, L. Abid, O. Ozdogan, O. Mitchenko, R. Patel (2019)
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.Atherosclerosis
D. Gaudet, J. López-Sendón, M. Averna, G. Bigot, M. Banach, A. Letierce, Megan Loy, R. Samuel, G. Manvelian, I. Batsu, P. Henry (2020)
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.European journal of preventive cardiology
(Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, et al. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association. 2021;10(8).)
Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, et al. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association. 2021;10(8).Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, et al. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association. 2021;10(8)., Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, et al. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. Journal of the American Heart Association. 2021;10(8).
C. Cannon, J. Lemos, R. Rosenson, C. Ballantyne, Yuyin Liu, Qi Gao, Tamara Palagashvilli, Shushama Alam, K. Mues, Deepak Bhatt, M. Kosiborod (2021)
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the USJAMA Cardiology, 6
IntroductionA high proportion of Canadian patients with acute myocardial infarction (AMI) do not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended by the Canadian Cardiovascular Society in 2021. This increases the risk of subsequent atherosclerotic cardiovascular disease (ASCVD) events. Here, we assess LDL-C levels and threshold achievement among patients by lipid-lowering therapies (LLT) received post-AMI.MethodsA retrospective cohort study of patients identified with AMI between 2015 and 2019 was conducted using administrative health databases in Alberta, Canada. Patients were grouped by their highest-intensity LLT post-AMI (proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) + another LLT; PCSK9i alone; ezetimibe + statin; statins (high, moderate, low intensity); or ezetimibe alone), and available LDL-C levels were examined in the year before and after LLT dispense date.ResultsThe cohort included 15,283 patients. In patients on PCSK9i + LLT, the median [95% confidence interval (CI)] LDL-C levels decreased from 2.7 (2.3–3.4) before to 0.9 (0.5–1.2) mmol/l after treatment, the largest decrease among treatment groups. In the ezetimibe + statin and high-intensity statin groups, median (95% CI) values after treatment were 1.5 (1.5–1.6) and 1.4 (1.4–1.4) mmol/l, respectively. The proportion of patients below the 1.8 mmol/l threshold increased by 77.7% in the PSCK9i + LLT group after treatment, compared to 45.4 and 32.4% in the ezetimibe + statin and high-intensity statin groups, respectively.ConclusionsIntensification with PCSK9i in AMI patients results in a greater proportion of patients achieving below the recommended LDL-C threshold versus statins and or ezetimibe alone. Increased focus on achieving below the LDL-C thresholds with additional LLT as required may benefit patient cardiovascular outcomes.
Cardiology and Therapy – Springer Journals
Published: Jun 1, 2023
Keywords: Proprotein convertase subtilisin/kexin type 9 inhibitors; Lipid-lowering therapy; Acute myocardial infarction; Low-density lipoprotein cholesterol; Real-world evidence
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.